Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record.

Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy

Itzhaki, Orit, Hovav, Einat, Ziporen, Yaara, Levy, Daphna, Kubi, Adva, Zikich, Dragoslav, Hershkovitz, Liat, Treves, Avraham J., Shalmon, Bruria, Zippel, Douglas, Markel, Gal, Shapira-Frommer, Ronnie, Schachter, Jacob, Besser, Michal J. · 2011 · Journal of Immunotherapy

Abstract

Treatment of metastatic melanoma patients with adoptively transferred tumor infiltrating lymphocytes (TIL) has developed into an effective therapy. Various studies reported objective responses of 50% and more. The use of unselected, minimally cultured, bulk TIL (Young-TIL) has simplified the TIL production process and may therefore, allow the accessibility of this approach to cancer centers worldwide. This article describes the precise process leading to the large-scale production of Young-TIL for therapy. We have enrolled 55 melanoma patients and optimized their Young-TIL generation process. Young-TIL cultures were successfully established for 51 of 55 (93%) patients in 16.7 ± 5.5 days. In a large-scale expansion procedure Young-TIL of 32 patients were further expanded to treatment levels, resulting in a final number of 4.5 x 10¹⁰ ± 2.0 x 10¹⁰ TIL. Fifteen of 31 (48%) patients, who were evaluated, achieved a clinical response, including 4 complete and 11 partial responses. We confirmed the significant correlation between short culture duration, high number of infused cells, and tumor regression. A high percentage of CD8 T cells in the infusion product was beneficial to achieve an objective response. All responding patients were treated with Young-TIL cultures established in < 20 days. In summary, we describe here an efficient and reliable method to generate Young-TIL for adoptive transfer therapy, which may easily be adopted by other cancer centers and can lead to objective responses in 50% of refractory melanoma patients. In the future this approach may be used also in other types of malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cji.0b013e318209c94c

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 169

Metadata

Authors
Itzhaki, O., Hovav, E., Ziporen, Y., Levy, D., Kubi, A., Zikich, D., Hershkovitz, L., Treves, A. J., Shalmon, B., Zippel, D., Markel, G., Shapira-Frommer, R., Schachter, J., & Besser, M. J.
Venue
Journal of Immunotherapy
Published
2011-03
Volume
34
Issue
2
Pages
212-220
ISSN
1524-9557 (ISSN-L)
OpenAlex
W2131473264
Cited by
169
References
0
FWCI
4.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy. https://app.cochat.ai/papers/10.1097/cji.0b013e318209c94c
The paper
Itzhaki, O., Hovav, E., Ziporen, Y., Levy, D., Kubi, A., Zikich, D., Hershkovitz, L., Treves, A. J., Shalmon, B., Zippel, D., Markel, G., Shapira-Frommer, R., Schachter, J., & Besser, M. J. (2011). Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy. Journal of Immunotherapy. https://doi.org/10.1097/cji.0b013e318209c94c

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.